These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 23027419)

  • 1. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
    Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G
    Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is NMDA receptor hypofunction in schizophrenia associated with a primary hyperglutamatergic state?
    Shim SS; Adityanjee
    Arch Gen Psychiatry; 2002 May; 59(5):466-7; author reply 467-8. PubMed ID: 11982452
    [No Abstract]   [Full Text] [Related]  

  • 5. Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.
    Jeevakumar V; Kroener S
    Cereb Cortex; 2016 Mar; 26(3):1117-29. PubMed ID: 25477370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia: Basic and Clinical.
    Coyle JT
    Adv Neurobiol; 2017; 15():255-280. PubMed ID: 28674984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia.
    Coyle JT
    Biochem Pharmacol; 2024 Oct; 228():116376. PubMed ID: 38906225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
    Coyle JT
    Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis.
    Iasevoli F; Polese D; Ambesi-Impiombato A; Muscettola G; de Bartolomeis A
    Neurosci Lett; 2007 Apr; 416(1):1-5. PubMed ID: 17317002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviewing the ketamine model for schizophrenia.
    Frohlich J; Van Horn JD
    J Psychopharmacol; 2014 Apr; 28(4):287-302. PubMed ID: 24257811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.
    Gonzalez-Burgos G; Lewis DA
    Schizophr Bull; 2012 Sep; 38(5):950-7. PubMed ID: 22355184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans.
    Moghaddam B; Krystal JH
    Schizophr Bull; 2012 Sep; 38(5):942-9. PubMed ID: 22899397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.